Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomePreferred Shares IssuedShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

vTv Therapeutics (VTVT) Share-based Compensation: 2015-2025

Historic Share-based Compensation for vTv Therapeutics (VTVT) over the last 10 years, with Sep 2025 value amounting to $1.0 million.

  • vTv Therapeutics' Share-based Compensation rose 18.05% to $1.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.6 million, marking a year-over-year increase of 53.10%. This contributed to the annual value of $2.8 million for FY2024, which is 74.71% up from last year.
  • Latest data reveals that vTv Therapeutics reported Share-based Compensation of $1.0 million as of Q3 2025, which was up 8.28% from $930,000 recorded in Q2 2025.
  • In the past 5 years, vTv Therapeutics' Share-based Compensation ranged from a high of $1.0 million in Q3 2025 and a low of $167,000 during Q2 2022.
  • In the last 3 years, vTv Therapeutics' Share-based Compensation had a median value of $813,000 in 2025 and averaged $644,091.
  • As far as peak fluctuations go, vTv Therapeutics' Share-based Compensation tumbled by 70.72% in 2022, and later soared by 269.55% in 2025.
  • Over the past 5 years, vTv Therapeutics' Share-based Compensation (Quarterly) stood at $994,000 in 2021, then slumped by 70.72% to $291,000 in 2022, then soared by 38.49% to $403,000 in 2023, then spiked by 104.71% to $825,000 in 2024, then rose by 18.05% to $1.0 million in 2025.
  • Its last three reported values are $1.0 million in Q3 2025, $930,000 for Q2 2025, and $813,000 during Q1 2025.